Belumosudil
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Also known as: belumosudil mesylate, KD025, rezurock, SLx-2119
Data last refreshed: (DrugCentral release 2024-11-01)
Key facts
Belumosudil is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2021. DrugCentral lists 2 molecular targets, including ROCK1 and ROCK2. Recorded indications include Chronic graft-versus-host disease (chronic GVHD).
- Approval status: onp (first approved 2021 by the FDA).
- Molecular targets: ROCK1 and ROCK2 (2 listed in DrugCentral).
- Indications: Chronic graft-versus-host disease (chronic GVHD).
- ATC code: L04AA48 (Selective immunosuppressants).
- Molecular formula: C26H24N6O2; molecular weight 452.52 g/mol.
Indications & contraindications
Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).
Indications (1)
- Chronic graft-versus-host disease (chronic GVHD)
Mechanism & targets
Molecular targets (2)
| Target | Gene | Action | Activity |
|---|---|---|---|
| Rho-associated protein kinase 1 | ROCK1 | inhibitor | IC50 5.52 |
| Rho-associated protein kinase 2 | ROCK2 | inhibitor | IC50 5.52 |
Regulatory approvals (1)
| Date | Agency | Marketed as | Applicant | Orphan |
|---|---|---|---|---|
| 2021-07-16 | FDA | — | KADMON PHARMA LLC | Yes |
ATC classification
| ATC code | Therapeutic hierarchy |
|---|---|
L04AA48 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants |
Reported adverse-event signals
Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.
| MedDRA term | LLR |
|---|---|
| Inappropriate schedule of product administration | 732.6 |
| Product use in unapproved indication | 553.2 |
| Hospitalisation | 128.2 |
| Chronic graft versus host disease | 90.3 |
| Alveolar proteinosis | 84.5 |
| Chronic graft versus host disease in skin | 66.7 |
| Disease progression | 63.5 |
| Chronic graft versus host disease in eye | 56.5 |
| Chronic graft versus host disease in intestine | 54.5 |
| Chronic graft versus host disease oral | 53.7 |
| Graft versus host disease | 52.4 |
| Graft versus host disease in lung | 46.6 |
Chemical structure
Full physicochemical, ADMET and 3D-structure analysis of Belumosudil is on its molecule page.
| Molecular formula | C26H24N6O2 |
|---|---|
| Molecular weight | 452.52 g/mol |
| CAS number | 911417-87-3 |
| InChIKey | GKHIVNAUVKXIIY-UHFFFAOYSA-N |
| PubChem CID | 11950170 |
Frequently asked questions
Answers are generated from the structured data on this page, not written by hand.
What is Belumosudil used for?
DrugCentral lists the following indications for Belumosudil: Chronic graft-versus-host disease (chronic GVHD).
How does Belumosudil work?
Its molecular targets in DrugCentral include ROCK1 (inhibitor) and ROCK2 (inhibitor).
When was Belumosudil first approved?
Belumosudil was first approved by the FDA in 2021.
What is the chemical formula of Belumosudil?
Belumosudil has the molecular formula C26H24N6O2 and a molecular weight of 452.52 g/mol.
Browse: all drugs starting with B · drug guides by category · protein targets A–Z.
Sources
- DrugCentral drug card 5467 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
- ChEMBL CHEMBL2005186 — compound record and bioactivity
- PubChem CID 11950170 — chemical identifiers
- DrugBank DB16703 — drug record
- FDA UNII 834YJF89WO — substance identity
- DailyMed: FDA labels for Belumosudil — current prescribing information (label search)
- UniProt Q13464 (ROCK1) — target protein
- UniProt O75116 (ROCK2) — target protein
- FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.